246 related articles for article (PubMed ID: 29589647)
1. Primary systemic amyloidosis with skin and cardiac involvement: a case report.
Trajber Horvat A; Trčko K; Jurčić V; Marko PB
Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar; 27(1):45-47. PubMed ID: 29589647
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Denman J; Manavi K; Cook M
Int J STD AIDS; 2017 Sep; 28(10):1045-1047. PubMed ID: 28632471
[TBL] [Abstract][Full Text] [Related]
3. IgG,kappa monoclonal gammopathy of unknown significance with AL amyloidosis simulating giant cell arteritis.
Pompilian VM; Tănăseanu Ş; Badea C; Zurac S; Socoliuc C; Badelita S; Botez E; Antohe M
Rom J Intern Med; 2017 Sep; 55(3):179-182. PubMed ID: 28467313
[TBL] [Abstract][Full Text] [Related]
4. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
[TBL] [Abstract][Full Text] [Related]
5. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
6. Multiorgan involvement by amyloid light chain amyloidosis.
Li G; Han D; Wei S; Wang H; Chen L
J Int Med Res; 2019 Apr; 47(4):1778-1786. PubMed ID: 30803274
[TBL] [Abstract][Full Text] [Related]
7. Hepatic veno-occlusive disease may be a rare characteristic of hepatic involvement in systemic amyloidosis: case report and literature review.
Zhu TY; Zhou GH; Chen XH; Teng XD; Sun JH
J Int Med Res; 2020 Feb; 48(2):300060520904857. PubMed ID: 32090649
[TBL] [Abstract][Full Text] [Related]
8. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Lee H; Tay J; Duggan P; McCulloch S; Neri P; Bahlis NJ; Jimenez-Zepeda VH
Eur J Haematol; 2021 Mar; 106(3):340-345. PubMed ID: 33197297
[TBL] [Abstract][Full Text] [Related]
9. Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report.
Lee ASY; Lee DZQ; Vasanwala FF
J Med Case Rep; 2016 Mar; 10():68. PubMed ID: 27026530
[TBL] [Abstract][Full Text] [Related]
10. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunoglobulin light-chain amyloidosis.
Comenzo RL
Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
[TBL] [Abstract][Full Text] [Related]
12. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E; Gavriatopoulou M; Roussou M; Bagratuni T; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Dialoupi I; Ntanasis-Stathopoulos I; Spyropoulou-Vlachou M; Psimenou E; Gakiopoulou H; Marinaki S; Papadopoulou E; Ntalianis A; Terpos E; Dimopoulos MA
Amyloid; 2018 Dec; 25(4):234-241. PubMed ID: 30663408
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.
Basset M; Milani P; Russo F; Lavatelli F; Nuvolone M; Foli A; Perlini S; Palladini G; Merlini G
Amyloid; 2017 Mar; 24(sup1):60-61. PubMed ID: 28434342
[No Abstract] [Full Text] [Related]
17. Progressive chorioretinal involvement in a patient with light-chain (AL) amyloidosis: a case report.
Augstburger E; Sahel JA; Audo I
BMC Ophthalmol; 2020 Feb; 20(1):59. PubMed ID: 32085748
[TBL] [Abstract][Full Text] [Related]
18. [An unusual presentation of Amyloidosis AL].
Zito A; De Pascalis A; Ria P; Armeni A; D'Amelio A; Napoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786185
[TBL] [Abstract][Full Text] [Related]
19. Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M; Nasr L; Khalid F; Allam S; Bouferraa Y; Batool S; Tayyeb M; Adroja S; Mammadii M; Anwer F; Raza S; Chaulagain CP
Oncotarget; 2023 Apr; 14():384-394. PubMed ID: 37185672
[TBL] [Abstract][Full Text] [Related]
20. Systemic amyloidosis-induced nail dystrophy.
Jo G; Shin DY; Mun JH
J Dtsch Dermatol Ges; 2019 Oct; 17(10):1057-1059. PubMed ID: 31538714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
